ACAA1 Is a Predictive Factor of Survival and Is Correlated With T Cell Infiltration in Non-Small Cell Lung Cancer

被引:9
作者
Feng, Huiyi [1 ]
Shen, Weixi [1 ]
机构
[1] Southern Med Univ, Dept Oncol, Shenzhen Hosp, Shenzhen, Peoples R China
关键词
non-small cell lung cancer; KRAS mutation; immune cell infiltration; immune checkpoint blockade; tumor metabolites; TUMOR MUTATIONAL BURDEN; MUTANT KRAS; MICROENVIRONMENT; COMPETITION;
D O I
10.3389/fonc.2020.564796
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung cancer (NSCLC) is the predominant subtype of lung cancers. KRAS mutation is the second most prevalent mutation in NSCLC. KRAS mutant cancer cells suppress the anti-tumor T cell response. However, the underlying mechanism is still unknown. Here, we analyzed the differential expression of acetyl-CoA acyltransferase 1 (ACAA1) in various types of cancers using the TIMER database and validated the results in the NSCLC cell line H1944. We silenced oncogenic KRAS by siRNA targeting KRAS(G13D), and employed an MAPK signaling pathway inhibitor to clarify the possible regulatory pathway. Moreover, we analyzed the correlation of ACAA1 expression level with B cells, CD4(+) T cells, CD8(+) T cells, neutrophils, macrophages, and dendritic cells. Correlations between expression of ACAA1 and several biomarkers of mutation burden were also tested. Finally, we evaluated the prognostic value of ACAA1 in a wide range of cancers using the Kaplan-Meier Plotter Database. We found lower expression of ACAA1 in tumor tissue than in adjacent normal tissue in various cancers. This result was confirmed using a GEO dataset. Knock-down of mutant KRAS resulted in increased ACAA1 mRNA level in H1944 cells. ACAA1 mRNA level was significantly upregulated in H1944 after treatment with MAPK pathway inhibitor sorafenib, indicating that oncogenic KRAS may downregulate ACAA1 through MAPK signaling. ACAA1 was negatively correlated with biomarkers of tumor mutation burden, including BRCA1, ATM, ATR, CDK1, PMS2, MSH2, and MDH6. Conversely, ACAA1 expression was positively correlated with infiltrating CD4(+) cells and with Th1, Th2, Treg cells in the lung tumor microenvironment. Finally, we showed that ACAA1 is a predictive factor for survival in several cancer types. In summary, decreased ACAA1 expression is correlated with poor prognosis and decreases immune infiltration of CD4(+) T cells in LUAD and LUSC. ACAA1 also predicts T cell exhaustion in LUSC. The mechanism underlying KRAS/ACAA1 axis-mediated regulation of immune cell infiltration requires further investigation.
引用
收藏
页数:13
相关论文
共 39 条
[1]   Human lung tumor FOXP+ Tregs upregulate four "Treg-locking" transcription factors [J].
Akimova, Tatiana ;
Zhang, Tianyi ;
Negorev, Dmitri ;
Singhal, Sunil ;
Stadanlick, Jason ;
Rao, Abhishek ;
Annunziata, Michael ;
Levine, Matthew H. ;
Beier, Ulf H. ;
Diamond, Joshua M. ;
Christie, Jason D. ;
Albelda, Steven M. ;
Eruslanov, Evgeniy B. ;
Hancock, Wayne W. .
JCI INSIGHT, 2017, 2 (16)
[2]  
Alfarouk Khalid O, 2014, Oncoscience, V1, P777
[3]  
Bedognetti D, 2017, EMERG TOP LIFE SCI, V1, P429, DOI 10.1042/ETLS20170142
[4]   Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors [J].
Berland, Lea ;
Heeke, Simon ;
Humbert, Olivier ;
Macocco, Adam ;
Long-Mira, Elodie ;
Lassalle, Sandra ;
Lespinet-Fabre, Virginie ;
Lalvee, Salome ;
Bordone, Olivier ;
Cohen, Charlotte ;
Leroy, Sylvie ;
Hofman, Veronique ;
Hofman, Paul ;
Ilie, Marius .
JOURNAL OF THORACIC DISEASE, 2019, 11 :S71-S80
[5]   High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients [J].
Cao, Dedong ;
Xu, Huilin ;
Xu, Ximing ;
Guo, Tao ;
Ge, Wei .
ONCOIMMUNOLOGY, 2019, 8 (09)
[6]   Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression [J].
Chang, Chih-Hao ;
Qiu, Jing ;
O'Sullivan, David ;
Buck, Michael D. ;
Noguchi, Takuro ;
Curtis, Jonathan D. ;
Chen, Qiongyu ;
Gindin, Mariel ;
Gubin, Matthew M. ;
van der Windt, Gerritje J. W. ;
Tonc, Elena ;
Schreiber, Robert D. ;
Pearce, Edward J. ;
Pearce, Erika L. .
CELL, 2015, 162 (06) :1229-1241
[7]  
DIASCARVALHO P, 2019, CANCERS, V11, DOI DOI 10.3390/CANCERS11122010
[8]  
DIASCARVALHO P, 2018, CANCER RES, V78, P7, DOI DOI 10.1158/0008-5472.CAN-17-2084
[9]   Somatic mutations affect key pathways in lung adenocarcinoma [J].
Ding, Li ;
Getz, Gad ;
Wheeler, David A. ;
Mardis, Elaine R. ;
McLellan, Michael D. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Greulich, Heidi ;
Muzny, Donna M. ;
Morgan, Margaret B. ;
Fulton, Lucinda ;
Fulton, Robert S. ;
Zhang, Qunyuan ;
Wendl, Michael C. ;
Lawrence, Michael S. ;
Larson, David E. ;
Chen, Ken ;
Dooling, David J. ;
Sabo, Aniko ;
Hawes, Alicia C. ;
Shen, Hua ;
Jhangiani, Shalini N. ;
Lewis, Lora R. ;
Hall, Otis ;
Zhu, Yiming ;
Mathew, Tittu ;
Ren, Yanru ;
Yao, Jiqiang ;
Scherer, Steven E. ;
Clerc, Kerstin ;
Metcalf, Ginger A. ;
Ng, Brian ;
Milosavljevic, Aleksandar ;
Gonzalez-Garay, Manuel L. ;
Osborne, John R. ;
Meyer, Rick ;
Shi, Xiaoqi ;
Tang, Yuzhu ;
Koboldt, Daniel C. ;
Lin, Ling ;
Abbott, Rachel ;
Miner, Tracie L. ;
Pohl, Craig ;
Fewell, Ginger ;
Haipek, Carrie ;
Schmidt, Heather ;
Dunford-Shore, Brian H. ;
Kraja, Aldi ;
Crosby, Seth D. ;
Sawyer, Christopher S. .
NATURE, 2008, 455 (7216) :1069-1075
[10]   Expanding roles for CD4T cells and their subpopulations in tumor immunity and therapy [J].
Dobrzanski, Mark J. .
FRONTIERS IN ONCOLOGY, 2013, 3